$16 Million Capital Raise to Progress Bionomics BNC210 PTSD Trial
- Written by PR Newswire
- Commitments received for a placement of A$15,991,634 at A$0.145 per share
- Significant participation from North American and European institutional and sophisticated investors
- This capital raising enables proceeding with the Phase 2b PTSD trial in mid-2021 as planned and sees the Company well capitalised
ADELAIDE, Australia, Feb. 10, 2021 /PRNewswire/...
